For patients undergoing percutaneous coronary intervention (PCI), tailoring antiplatelet therapy based on the results of platelet function testing makes no difference in the risk of recurrent ischemic ...
In patients undergoing percutaneous coronary intervention (PCI), intensifying antiplatelet therapy based on platelet reactivity testing reduces cardiovascular mortality and stent thrombosis, according ...
August 28, 2012 (Munich, Germany) — The debate as to whether platelet function should be routinely measured in patients undergoing PCI has been raised again with two new studies presented at the ...
BRAINTREE, Mass., Nov. 20, 2019 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient ...
March 6, 2009 (Munich, Germany) — More evidence that patients with a low platelet responsiveness to clopidogrel have an increased risk of stent thrombosis has come from a new study, with the ...
Platelet function testing technology will complement Roche's full line of coagulation analyzers targeted for introduction in US and Canada in 2014 The acquisition supports plans Roche announced in ...
The RECLOSE 2–ACS (Responsiveness to Clopidogrel and Stent Thrombosis 2–ACS) trial from Italy provides new information about platelet reactivity but doesn't answer any of the key questions about the ...
Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...
A new study successfully identifies new genetic variants involved in the formation of platelets and more importantly, defines how genes near these variants affect platelet size and number using a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results